MME and breast cancer: In a breast cancer patient-derived xenograft model, blockade of GPR77 with neutralizing monoclonal antibody markedly reduced the infiltration of CD10+GPR77+ CAFs and the proportion of ALDH1+ CSCs, resulting in decreased tumorigenesis and increased chemosensitivity [163].